BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25794069)

  • 21. Clear Cell Papillary Renal Cell Carcinoma: A Recent Entity With Distinct Imaging Patterns.
    Tordjman M; Dbjay J; Chamouni A; Morini A; Timsit MO; Mejean A; Vasiliu V; Eiss D; Correas JM; Verkarre V; Helenon O
    AJR Am J Roentgenol; 2020 Mar; 214(3):579-587. PubMed ID: 31770020
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of Utility of Histogram Apparent Diffusion Coefficient and R2* for Differentiation of Low-Grade From High-Grade Clear Cell Renal Cell Carcinoma.
    Zhang YD; Wu CJ; Wang Q; Zhang J; Wang XN; Liu XS; Shi HB
    AJR Am J Roentgenol; 2015 Aug; 205(2):W193-201. PubMed ID: 26204307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
    Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
    Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.
    Paner GP; Amin MB; Alvarado-Cabrero I; Young AN; Stricker HJ; Moch H; Lyles RH
    Am J Surg Pathol; 2010 Sep; 34(9):1233-40. PubMed ID: 20679882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.
    Amin MB; Paner GP; Alvarado-Cabrero I; Young AN; Stricker HJ; Lyles RH; Moch H
    Am J Surg Pathol; 2008 Dec; 32(12):1822-34. PubMed ID: 18813125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MR imaging follow-up after percutaneous radiofrequency ablation of renal cell carcinoma: findings in 18 patients during first 6 months.
    Merkle EM; Nour SG; Lewin JS
    Radiology; 2005 Jun; 235(3):1065-71. PubMed ID: 15914485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.
    Neuzillet Y; Tillou X; Mathieu R; Long JA; Gigante M; Paparel P; Poissonnier L; Baumert H; Escudier B; Lang H; Rioux-Leclercq N; Bigot P; Bernhard JC; Albiges L; Bastien L; Petit J; Saint F; Bruyere F; Boutin JM; Brichart N; Karam G; Branchereau J; Ferriere JM; Wallerand H; Barbet S; Elkentaoui H; Hubert J; Feuillu B; Theveniaud PE; Villers A; Zini L; Descazeaux A; Roupret M; Barrou B; Fehri K; Lebret T; Tostain J; Terrier JE; Terrier N; Martin L; Dugardin F; Galliot I; Staerman F; Azemar MD; Irani J; Tisserand B; Timsit MO; Sallusto F; Rischmann P; Guy L; Valeri A; Deruelle C; Azzouzi AR; Chautard D; Mejean A; Salomon L; Rigaud J; Pfister C; Soulié M; Kleinclauss F; Badet L; Patard JJ; ;
    Eur Urol; 2011 Aug; 60(2):366-73. PubMed ID: 21377780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Differential diagnosis between renal cell carcinoma associated with XP11.2 translocation/TFE gene fusion and papillary renal cell carcinoma based on CT and MRI findings].
    Zhu Q; Zhu W; Wu J; Fu J; Chen W; Wang Z
    Zhonghua Yi Xue Za Zhi; 2014 May; 94(19):1470-2. PubMed ID: 25143166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of T1-Weighted MRI to Detect Intratumoral Hemorrhage Within Papillary Renal Cell Carcinoma as a Feature Differentiating From Angiomyolipoma Without Visible Fat.
    Murray CA; Quon M; McInnes MD; van der Pol CB; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2016 Sep; 207(3):585-91. PubMed ID: 27275530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Characterization and staging of renal tumors: significance of MRI diagnostics].
    Kalinka A; Gerlach A; Arlart IP; Günes N; Hauser TK; Würstlin S; Bosse A
    Rofo; 2006 Mar; 178(3):298-305. PubMed ID: 16508837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal cell carcinoma in patients with acquired cystic disease of the kidney: assessment using a combination of T2-weighted, diffusion-weighted, and chemical-shift MRI without the use of contrast material.
    Akita H; Jinzaki M; Akita A; Mikami S; Oya M; Kuribayashi S
    J Magn Reson Imaging; 2014 Apr; 39(4):924-30. PubMed ID: 24123320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of the pseudocapsule on MRI of renal neoplasms and its potential application for local staging: a retrospective study.
    Roy C; El Ghali S; Buy X; Lindner V; Lang H; Saussine C; Jacqmin D
    AJR Am J Roentgenol; 2005 Jan; 184(1):113-20. PubMed ID: 15615960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MSCT and MRI findings of collecting duct carcinoma.
    Zhu Q; Wu J; Wang Z; Zhu W; Chen W; Wang S
    Clin Radiol; 2013 Oct; 68(10):1002-7. PubMed ID: 23726725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unenhanced CT and MRI Parameters That Can Be Used to Reliably Predict Fat-Invisible Angiomyolipoma.
    Jeong CJ; Park BK; Park JJ; Kim CK
    AJR Am J Roentgenol; 2016 Feb; 206(2):340-7. PubMed ID: 26797361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.
    Park YH; Baik KD; Lee YJ; Ku JH; Kim HH; Kwak C
    BJU Int; 2012 Dec; 110(11 Pt B):E553-8. PubMed ID: 22578274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of high nuclear grade in patients with pathologic T1a renal cell carcinoma.
    Suzuki K; Mizuno R; Mikami S; Tanaka N; Kanao K; Kikuchi E; Miyajima A; Nakagawa K; Oya M
    Jpn J Clin Oncol; 2012 Sep; 42(9):831-5. PubMed ID: 22811408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution.
    Przybycin CG; Cronin AM; Darvishian F; Gopalan A; Al-Ahmadie HA; Fine SW; Chen YB; Bernstein M; Russo P; Reuter VE; Tickoo SK
    Am J Surg Pathol; 2011 Jul; 35(7):962-70. PubMed ID: 21602658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients.
    Klatte T; Seitz C; Waldert M; de Martino M; Kikic Z; Böhmig GA; Haitel A; Schmidbauer J; Marberger M; Remzi M
    BJU Int; 2010 May; 105(9):1260-5. PubMed ID: 19818071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.